{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["Colorectal Cancer","Head and Neck Cancer","Colorectal Neoplasms","Head and Neck Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms","Head And Neck Neoplasms","Head And Neck Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2164428"],"location":["United States"],"study_start_month":["4"],"keyword":["Cetuximab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer","description":"The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck.","dates":{"creation":"2014-04-15"},"accession":"2164428","cross_references":{"ClinicalTrials___gov":["NCT02110082"]}}